Description
Indication & Scope
Jascayd® Nerandomilast Tablets treats adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) to slow progressive fibrotic lung tissue damage and decline in pulmonary function.
- Mechanism: Nerandomilast is a selective PDE4B phosphodiesterase inhibitor. It elevates intracellular cAMP concentrations in lung fibroblasts and inflammatory immune cells, suppresses pro-fibrotic cytokine release, inhibits fibroblast proliferation and extracellular matrix collagen deposition, delivering combined anti-inflammatory and anti-fibrotic pulmonary protective effects.
- Drug class: Selective PDE4B inhibitor; oral anti-fibrotic respiratory therapeutic agent.
- Clinical use: Long-term maintenance treatment for idiopathic pulmonary fibrosis; slows forced vital capacity decline, reduces acute exacerbation risk and improves patient exercise tolerance.
| Generic Name | Nerandomilast Tablets |
| Brand Name | Jascayd |
| Ingredient | Nerandomilast |
| Dosage Form | Tablets |
| Package | 9mg*10 tablets*3 blisters/box;
9mg*10 tablets*6 blisters/box; 18mg*10 tablets*3 blisters/box; 18mg*10 tablets*6 blisters/box |
| Conditions Treated | Idiopathic pulmonary fibrosis (IPF) in adult patients |
| Taboos | Known severe hypersensitivity to nerandomilast or tablet excipients; patients with decompensated severe liver cirrhosis |
| Place of origin | Binger Strasse 173, 55216 Ingelheim am Rhein, Germany |
| Prescription type | Prescription-only |
| Storage Conditions | Store original sealed bottles at 20°C–25°C, protected from moisture and direct sunlight |
| Manufacturer | Boehringer Ingelheim International GmbH |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20250125; HJ20250126 |
| Approval Date | Oct 21, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: 18 mg oral twice daily, approximately 12 hours apart. Reduce to 9 mg twice daily for persistent gastrointestinal adverse reactions.
Time: Administer morning and evening at consistent 12-hour intervals, with or without meals.
Instructions for use: Tablets may be swallowed whole or dispersed in room-temperature water for patients with swallowing difficulty. Baseline liver function testing is required before therapy initiation.
Interaction: Systemic CYP3A4 inhibitors increase nerandomilast plasma levels and gastrointestinal side effect frequency; concurrent other PDE4 inhibitors are contraindicated.
Side effects:
1. Common adverse reactions: diarrhea, nausea, abdominal pain, headache, weight loss.
2. Severe rare side effects: severe psychiatric mood disorders, significant hepatic enzyme elevation.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the exclusive therapeutic indication of Nerandomilast Tablets?
It is used for adult patients diagnosed with idiopathic pulmonary fibrosis to delay lung function deterioration.
What is the conventional dose and adjustment rule of Nerandomilast Tablets?
The conventional dose is 18 mg twice daily, which can be reduced to 9 mg twice daily for severe gastrointestinal reactions.
What patients cannot use Nerandomilast Tablets?
Patients with severe drug hypersensitivity and decompensated severe liver cirrhosis are contraindicated.
What is the shelf life of unopened Nerandomilast Tablets under standard storage?
The shelf life is 36 months under sealed and standardized room temperature storage.
Jascayd® | Nerandomilast Tablets | IPF | DengYueRX
INN: Nerandomilast Tablets
Indications: Idiopathic pulmonary fibrosis (IPF)
Dosage Form: Tablets
Strength: 9mg/tablet; 18mg/tablet
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
